Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.64
MDCO's Cash-to-Debt is ranked lower than
66% of the 815 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.12 vs. MDCO: 0.64 )
Ranked among companies with meaningful Cash-to-Debt only.
MDCO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.64  Med: No Debt Max: No Debt
Current: 0.64
Equity-to-Asset 0.32
MDCO's Equity-to-Asset is ranked lower than
86% of the 739 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. MDCO: 0.32 )
Ranked among companies with meaningful Equity-to-Asset only.
MDCO' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.32  Med: 0.76 Max: 0.89
Current: 0.32
0.32
0.89
Piotroski F-Score: 2
Altman Z-Score: 0.91
Beneish M-Score: -3.34
WACC vs ROIC
5.83%
-46.23%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -262.15
MDCO's Operating Margin % is ranked lower than
90% of the 767 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.94 vs. MDCO: -262.15 )
Ranked among companies with meaningful Operating Margin % only.
MDCO' s Operating Margin % Range Over the Past 10 Years
Min: -262.15  Med: -3.69 Max: 14.87
Current: -262.15
-262.15
14.87
Net Margin % -91.25
MDCO's Net Margin % is ranked lower than
86% of the 769 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.26 vs. MDCO: -91.25 )
Ranked among companies with meaningful Net Margin % only.
MDCO' s Net Margin % Range Over the Past 10 Years
Min: -114.16  Med: -3.66 Max: 26.38
Current: -91.25
-114.16
26.38
ROE % -18.99
MDCO's ROE % is ranked lower than
79% of the 792 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.84 vs. MDCO: -18.99 )
Ranked among companies with meaningful ROE % only.
MDCO' s ROE % Range Over the Past 10 Years
Min: -42.69  Med: -3.25 Max: 35
Current: -18.99
-42.69
35
ROA % -7.59
MDCO's ROA % is ranked lower than
76% of the 821 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.58 vs. MDCO: -7.59 )
Ranked among companies with meaningful ROA % only.
MDCO' s ROA % Range Over the Past 10 Years
Min: -20  Med: -2.03 Max: 24.65
Current: -7.59
-20
24.65
ROC (Joel Greenblatt) % -260.49
MDCO's ROC (Joel Greenblatt) % is ranked lower than
86% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.07 vs. MDCO: -260.49 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
MDCO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -260.49  Med: -18.84 Max: 402.9
Current: -260.49
-260.49
402.9
3-Year Revenue Growth Rate -37.80
MDCO's 3-Year Revenue Growth Rate is ranked lower than
94% of the 640 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.20 vs. MDCO: -37.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
MDCO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 7.95 Max: 88.5
Current: -37.8
0
88.5
GuruFocus has detected 4 Warning Signs with The Medicines Co $MDCO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» MDCO's 30-Y Financials

Financials (Next Earnings Date: 2017-10-26 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NAS:IRWD, NAS:ENDP, NAS:SUPN, OTCPK:EVTCY, NAS:RDUS, NAS:HZNP, NAS:PCRX, NAS:OPK, NAS:PAHC, NAS:AKRX, NAS:MNTA, NAS:EGRX, NYSE:DPLO, NAS:IPXL, OTCPK:GNMLF, OTCPK:STDAF, OTCPK:KHTRF, OTCPK:NPPNY, NAS:SGYP, OTCPK:TWMJF » details
Traded in other countries:MZN.Germany,
Headquarter Location:USA
The Medicines Co is a pharmaceutical company. It provides transformational solutions to address the most pressing healthcare needs facing patients, physicians and providers. The company's products are Angiomax, Ionsys, Minocin for injection and Orbactiv.

The Medicines Company is a pharmaceutical firm that provides products to the U.S. hospital market. The company's primary commercial product, Angiomax, is an anticoagulant drug used in conjunction with aspirin for patients undergoing angioplasty. Medicines recently commercialized a new drug, Cleviprex, which is designed to control blood pressure in intensive-care settings.

Top Ranked Articles about The Medicines Co

First Eagle's Investments of the Last 2 Quarters Guru's 3rd- and 4th-quarter purchases
First Eagle Investment (Trades, Portfolio) is an independent firm with an estimated $97 billion in assets under management. The firm manages a portfolio composed of 334 stocks with a total value of $39.105 billion. In the third and fourth quarters of 2016 the guru bought shares in the following stocks: Read more...
6 Stocks Traded by Insiders Last Week Officers trade shares of Medicines Co., VBI Vaccines, TransDigm Group, Headwaters, Cooper-Standard, AutoZone
The All-in-One Screener can be used to find insider trades from the past week. Under the Insiders tab, change the settings for All Insider Buying to “$200,000+” and the duration to “December 2016” and All Insider Sales to “$5,000,000+.” Read more...

Ratios

vs
industry
vs
history
PB Ratio 5.44
MDCO's PB Ratio is ranked lower than
77% of the 761 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.88 vs. MDCO: 5.44 )
Ranked among companies with meaningful PB Ratio only.
MDCO' s PB Ratio Range Over the Past 10 Years
Min: 1.14  Med: 2.5 Max: 7.56
Current: 5.44
1.14
7.56
PS Ratio 19.55
MDCO's PS Ratio is ranked lower than
89% of the 743 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.96 vs. MDCO: 19.55 )
Ranked among companies with meaningful PS Ratio only.
MDCO' s PS Ratio Range Over the Past 10 Years
Min: 0.9  Med: 2.93 Max: 27.18
Current: 19.55
0.9
27.18
Current Ratio 1.04
MDCO's Current Ratio is ranked lower than
88% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. MDCO: 1.04 )
Ranked among companies with meaningful Current Ratio only.
MDCO' s Current Ratio Range Over the Past 10 Years
Min: 0.75  Med: 3.99 Max: 10.09
Current: 1.04
0.75
10.09
Quick Ratio 0.90
MDCO's Quick Ratio is ranked lower than
81% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.84 vs. MDCO: 0.90 )
Ranked among companies with meaningful Quick Ratio only.
MDCO' s Quick Ratio Range Over the Past 10 Years
Min: 0.75  Med: 3.48 Max: 9.44
Current: 0.9
0.75
9.44
Days Inventory 392.96
MDCO's Days Inventory is ranked lower than
95% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 117.36 vs. MDCO: 392.96 )
Ranked among companies with meaningful Days Inventory only.
MDCO' s Days Inventory Range Over the Past 10 Years
Min: 72.24  Med: 130.74 Max: 392.96
Current: 392.96
72.24
392.96
Days Sales Outstanding 58.04
MDCO's Days Sales Outstanding is ranked higher than
66% of the 651 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.70 vs. MDCO: 58.04 )
Ranked among companies with meaningful Days Sales Outstanding only.
MDCO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 26.9  Med: 52.08 Max: 86.14
Current: 58.04
26.9
86.14
Days Payable 96.79
MDCO's Days Payable is ranked higher than
67% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.86 vs. MDCO: 96.79 )
Ranked among companies with meaningful Days Payable only.
MDCO' s Days Payable Range Over the Past 10 Years
Min: 15.33  Med: 48.79 Max: 145.55
Current: 96.79
15.33
145.55

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -3.30
MDCO's 3-Year Average Share Buyback Ratio is ranked higher than
55% of the 477 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.30 vs. MDCO: -3.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MDCO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -85.1  Med: -4.85 Max: 0
Current: -3.3
-85.1
0

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 6.68
MDCO's Price-to-Median-PS-Value is ranked lower than
97% of the 718 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.08 vs. MDCO: 6.68 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MDCO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.33  Med: 1.37 Max: 61.83
Current: 6.68
0.33
61.83
Earnings Yield (Greenblatt) % -2.76
MDCO's Earnings Yield (Greenblatt) % is ranked lower than
75% of the 820 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.97 vs. MDCO: -2.76 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MDCO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -14  Med: 0.5 Max: 15.2
Current: -2.76
-14
15.2
Forward Rate of Return (Yacktman) % -10.80
MDCO's Forward Rate of Return (Yacktman) % is ranked lower than
87% of the 381 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.46 vs. MDCO: -10.80 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
MDCO' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -16.6  Med: 2.2 Max: 5.2
Current: -10.8
-16.6
5.2

More Statistics

Revenue (TTM) (Mil) $141.75
EPS (TTM) $ -1.91
Beta0.58
Short Percentage of Float63.49%
52-Week Range $30.80 - 55.95
Shares Outstanding (Mil)72.17

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 105 138 232
EPS ($) -5.05 -3.71 -3.46
EPS without NRI ($) -5.05 -3.71 -3.46
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for MDCO

Headlines

Articles On GuruFocus.com
Vaccine Small-Cap Just Took a Big Step Forward Jun 26 2017 
Annaly Capital Management: Attractive 9.5% Dividend Yield, but Interest Rates Are a Major Risk Jun 25 2017 
Never a Better Time to Pile on Chipotle Jun 25 2017 
Oracle Slowly Gaining Momentum on the Cloud Front Jun 26 2017 
Boeing Takes Lead Over Airbus With $30 Billion Worth of Orders on Day 1 of Paris Air Show Jun 25 2017 
Berkshire Hathaway’s Recent Investment: Home Capital Group Jun 25 2017 
Stocks That Fell to 3-Year Lows in the Week of June 23 Jun 24 2017 
Weekly Top Insider Buys Highlight for the Week of June 23 Jun 24 2017 
ID Watchdog Announces Special and Annual General Meeting Date and Record Date Jun 23 2017 
Ironclad Performance Wear Postpones 2017 Annual Meeting of Stockholders Jun 23 2017 

More From Other Websites
Why Is Alnylam (ALNY) Up 31.2% Since the Last Earnings Report? Jun 08 2017
Edited Transcript of MDCO earnings conference call or presentation 26-Apr-17 12:30pm GMT Jun 06 2017
Top Losers in the Healthcare Sector: May 22–26, 2017 May 31 2017
The Medicines Company to Present Data at ASM Microbe 2017 on Infectious Disease Portfolio Including... May 30 2017
Regeneron Presents Positive Phase II Data on HoFH Candidate May 25 2017
ETFs with exposure to The Medicines Co. : May 22, 2017 May 22 2017
This Fund’s Picks Gained 200% In A Year And Why No One Knows About It May 16 2017
The Medicines Co. :MDCO-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017 May 09 2017
Alnylam (ALNY) Q1 Loss Wider than Expected, Revenues Up Y/Y May 08 2017
Do Options Traders Know Something About Medicines Company (MDCO) Stock We Don't? May 08 2017
The Medicines Company to Participate in the Bank of America Merrill Lynch 2017 Health Care... May 04 2017
The Medicines Company (MDCO) Q1 Loss Wider Than Expected Apr 27 2017
Blog Coverage Medicines Co. Reaches Agreement with FDA for the Phase III Trial for Inclisiran Apr 27 2017
Amgen Trips Amid Rivals: Sales Miss By $100 Million, But Earnings Top Apr 26 2017
The Medicines Co. – Value Analysis (NASDAQ:MDCO) : April 26, 2017 Apr 26 2017
Medicines Co. reports 1Q loss Apr 26 2017
The Medicines Company Reports First-Quarter 2017 Financial Results Apr 26 2017
The Medicines Company and Alnylam Pharmaceuticals Announce Agreement with FDA on Phase III Clinical... Apr 26 2017
The Medicines Co. breached its 50 day moving average in a Bearish Manner : MDCO-US : April 25, 2017 Apr 25 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}